SIG 018
Alternative Names: SIG-018Latest Information Update: 18 Aug 2023
At a glance
- Originator Sigilon Therapeutics
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Mucopolysaccharidosis II
Most Recent Events
- 14 Aug 2023 Sigilon Therapeutics has been acquired by Eli Lilly and Company
- 23 Sep 2020 SIG 018 is available for licensing as of 23 Sep 2020. https://sigilon.com/
- 23 Sep 2020 Early research in Mucopolysaccharidosis II in USA (Implant), before September 2020 (Sigilon Therapeutics pipeline, September 2020)